It’s little surprise that Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer. With a long-held interest in the field allied to his scientific training, Tim is a firm believer in the transformative power of life sciences and the remarkable impact they can have on people’s lives.
Today Tim's principal focus is on patents and related rights, providing strategic advice and litigation expertise in the English Court and Unified Patents Court principally to innovator biotech and pharma companies. Tim has advised on numerous blockbuster treatments including monoclonal antibody therapies and other biologics, as well as other innovative technologies.
Tim enjoys helping his clients understand, enforce and defend their IP rights and minimise their risks. The approach taken to this work is always collaborative, often working as part of a multi-jurisdictional team he relishes the challenge of forming and deploying creative legal and commercial strategies.
Highly regarded in the wider industry, Tim is a member of the European Patent Lawyers Association (EPLAW) and teaches on Oxford University's Postgraduate Intellectual Property Diploma.
Helping you succeed in tomorrow's world
I enjoy developing and supporting the next generation of lawyers and entrepreneurs. I take pleasure from regularly lecturing, teaching, and working with start-ups and spin-outs to help them understand how to protect their innovations and minimise IP risks.
Advised Amgen on the commerciation of its eculizumab biosimilar (BEKEMV®) in the UK High Court, UPC litigation and pan-European strategy.
Advised Santen on the protection and enforcement of its tafluprost (TAFLOTAN®) patent rights in the UK and across Europe.
Represented Anstar to defend its photoinitiator chemical business in UK High Court patent infringement proceedings.
Advised a large pharmaceutical company in relation to patent rights in direct oral anticoagulants (DOACs).
Represented Block, Inc. (formerly Square, Inc.) defending High Court litigation concerning IP rights in bitcoin.
Advised Eurosemillas SA in relation to the UK aspects of its plant variety rights in a multinational dispute.
Supported Dialight plc in the renegotiation of its patent licence from Signify and the commercialisation of its own patent portfolio.
Advised A-Gas on its IP strategy and enforcement.
Insights
Trade secrets remain the sticking point in global debate over a vaccine IP waiver
Timely trials: are UK patent proceedings becoming easier to expedite?
The future regulation of AI: UKIPO consults on patent protection
Supreme Court gives certainty to patentees in unlawful means economic tort claims
Court of Appeal's DABUS decision highlights the debate on patents for AI-derived inventions
UK sets out plans to diverge from EU regime on gene editing in plants
The government has signalled its intention to pave the way for gene-edited crops following a consultation on departing from EU...
The government has vision for the UK as the world's leading hub for life sciences
Details on the funding of the 10-year strategy, which builds on the UK's world-class capability and on lessons from the...
Court of Appeal finds inventors must be human
An artificial intelligence (AI) machine cannot be an 'inventor' for purpose of Patents Act 1977 and owner of machinery cannot...
Wind power boom is fanning high-stakes international patent activity
The ancient form of power generation is now the world's number two source of renewable electricity, and its high profile...
Court of Appeal judge provides obiter guidance on the correct application of Formstein defence in the UK
The decision provides a further example that the UK courts are likely to accept the Formstein defence, when required, and...
Car wars: how tech ownership battles will decide the future leaders of autonomous vehicles
An upsurge in patent filings by new competitors in the autonomous vehicles arena means incumbents need to strengthen their IP...
Debate intensifies over a vaccine IP waiver's impact on future pharma and biotech discoveries
Does a proposed patent suspension backed by Washington open a Pandora's box for vaccine R&D and investment?